Document is current
Any future updates will be listed below
-
Authors
Di Martino, Julie S. https://orcid.org/0000-0002-2163-0736
Nobre, Ana Rita
Mondal, Chandrani
Taha, Isra
Farias, Eduardo F.
Fertig, Elana J.
Naba, Alexandra https://orcid.org/0000-0002-4796-5614
Aguirre-Ghiso, Julio A. https://orcid.org/0000-0002-6694-6507
Bravo-Cordero, Jose Javier https://orcid.org/0000-0001-9481-1231
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA078207, K22CA196750, R01CA244780, CA196521)
Susan G. Komen (CCR18547848)
- License Information
-
More Information
Article History
Received: 1 June 2021
Accepted: 21 October 2021
First Online: 13 December 2021
Competing interests
: E.J.F. is a member of the scientific advisory board of Viosera Therapeutics. J.A.A.-G. is a scientific co-founder of, scientific advisory board member of and equity owner in HiberCell and receives financial compensation as a consultant for HiberCell, a Mount Sinai spin-off company focused on therapeutics that prevent or delay cancer recurrence. The other authors declare no competing interests.
